Description

Clinical Evidence

• In a 2023 Phase 2 trial, participants on high-dose retatrutide lost up to 24.2% of body weight over 48 weeks, rivaling or exceeding bariatric surgery outcomes.
• Significant improvements were also observed in HbA1c levels, liver fat reduction, and cardiovascular biomarkers.
• Retatrutide showed greater weight loss than semaglutide and tirzepatide in similar patient populations, though direct comparisons are still under investigation.

Potential Side Effects

As with other incretin-based therapies, side effects are generally gastrointestinal and transient:
• Nausea and vomiting
• Diarrhea or constipation
• Abdominal pain
• Loss of appetite
• Mild fatigue or dizziness
• Rare cases: pancreatitis, gallbladder disease, or increased heart rate
Side effects tend to subside with dose escalation and patient adaptation.

Disclaimer

This product is strictly for laboratory research purposes only. It is not intended for human or veterinary use. Any mention of clinical data is for informational and educational purposes. Only licensed professionals should handle and experiment with this peptide in a controlled setting.